Tratamiento de la Enfermedad de Dupuytren en España

Resumen

Objetivos Nuestro objetivo consiste en valorar la situación actual en España del tratamiento de la enfermedad de Dupuytren mediante una encuesta realizada a los cirujanos de mano españoles y compararla con una encuesta similar realizada en España antes de la comercialización de la colagenasa en Europa.

Material y Métodos Se remite una encuesta a los socios de la Sociedad Española de Cirugía de la Mano (SECMA) con 30 preguntas divididas en 4 bloques: aspectos demográficos, opinión general del tratamiento de la enfermedad de Dupuytren, casos clínicos y repercusión de la introducción de la colagenasa Clostridium Histolyticum en el tratamiento.

Resultados La tasa de respuesta fue del 38,2% sobre un total de 332 socios. La mayor parte de los participantes se consideró como cirujanos no noveles. La fasciectomía parcial es la técnica más frecuentemente utilizada (73% de los encuestados) y considerada de primera elección (61,9%) seguida por la colagenasa (23% y 31% respectivamente). Más de la mitad de los encuestados consideró que ha habido un cambio en el modo de afrontar la enfermedad de Dupuytren en los últimos 5 años. Con respecto a la colagenasa, actualmente el uso de los protocolos iniciales se ha abandonado, aunque el protocolo de tratamiento más habitual sigue siendo la administración de una dosis desechando el resto del vial.

Conclusiones Actualmente la fasciectomía parcial es la técnica preferida y más frecuentemente utilizada en la enfermedad de Dupuytren seguida de la colagenasa en España.

Abstract

Objectives Our objective is to assess the current situation in Spain of Dupuytren’s disease treatment through a survey of Spanish hand surgeons and compare it with a similar survey conducted in Spain before the commercialization of collagenase in Europe.

Methods A survey was sent to the members of the Spanish Society of Hand Surgery (SECMA) with 30 questions divided into four blocks: demographics, general opinion of Dupuytren’s disease treatment, clinical reports and impact of the introduction of collagenase Clostridium Histolyticum as treatment for this pathology.

Results The response rate was 38.2% over a total of 332 members. The major part of the participants were considered as non-novel surgeons. Partial fasciectomy is the most frequently used technique (73% of respondents) and considered first choice treatment (61.9%) followed by collagenase (23% and 31% respectively). More than half of the respondents considered that there has been a change in how to deal with Dupuytren’s disease in the last 5 years. With regarding collagenase, currently the use of the initial protocols has been abandoned, although the most common treatment protocol remains the administration of a dose discarding the rest of the bottle.

Conclusions Currently, partial fasciectomy is the preferred technique and more frequently used in Dupuytren’s disease followed by collagenase in Spain.

Palabras clave

enfermedad de Dupuytren - fasciectomía - colagenasa - encuesta

Keywords

Dupuytren’s disease - fasciectomy - collagenase - survey

• Bibliografía

• 1 Hueston J. Lessons in Dupuytren's disease. Ann Chir Main Memb Super 1992; 11 (05) 349-354 . Doi:10.1016/S0753-9053(05)80269-8
• 2 Hurst LC, Badalamente MA, Hentz VR. , et al; CORD I Study Group. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med 2009; 361 (10) 968-979 . Doi:10.1056/NEJMoa0810866
• 3 Sanjuan-Cerveró R, Vazquez-Ferreiro P, Gomez-Herrero D, Carrera-Hueso FJ. Efficacy of Collagenase Clostridium Histolyticum for Dupuytren Disease: A Systematic Review. Rev Iberoam Cir Mano 2017; 45 (02) 70-88
• 4 Muñoz-Peñin R, Lwoff N, Renú JMA. Enfermedad de Dupuytren, una vista panorámica de nuestro entorno. Rev Iberoam Cir Mano 2011; 39 (02) 126-134 . Doi:10.1055/s-0037-1606801
• 5 Naam NH. Functional outcome of collagenase injections compared with fasciectomy in treatment of Dupuytren's contracture. Hand (N Y) 2013; 8 (04) 410-416 . Doi:10.1007/s11552-013-9540-7
• 6 Sanjuan-Cerveró R, Carrera-Hueso FJ, Vazquez-Ferreiro P, Gomez-Herrero D. Adverse Effects of Collagenase in the Treatment of Dupuytren Disease: A Systematic Review. BioDrugs 2017; 31 (02) 105-115 . Doi:10.1007/s40259-017-0211-z
• 7 Chen NC, Shauver MJ, Chung KC. Cost-effectiveness of open partial fasciectomy, needle aponeurotomy, and collagenase injection for dupuytren contracture. J Hand Surg Am 2011; 36 (11) 1826-1834.e32 . Doi:10.1016/j.jhsa.2011.08.004
• 8 Mehta S, Belcher HJCR. A single-centre cost comparison analysis of collagenase injection versus surgical fasciectomy for Dupuytren's contracture of the hand. J Plast Reconstr Aesthet Surg 2014; 67 (03) 368-372 . Doi:10.1016/j.bjps.2013.12.030
• 9 Sanjuan Cerveró R, Franco Ferrando N, Poquet Jornet J. Use of resources and costs associated with the treatment of Dupuytren's contracture at an orthopedics and traumatology surgery department in Denia (Spain): collagenase clostridium hystolyticum versus subtotal fasciectomy. BMC Musculoskelet Disord 2013; 14 (01) 293 . DOI: 10.1186/1471-2474-14-293
• 10 Warwick D. Collagenase: What We May Never Know (A Discussion). In: Werker PMN, Dias J, Eaton C, Reichert B, Wach W. , eds. Dupuytren Disease and Related Diseases - The Cutting Edge. Springer International Publishing; 2017: 145-149 . doi:10.1007/978-3-319-32199-8_19
• 11 Jupiter J, Burke D. Scott's parabola and the rise of the medical-industrial complex. Hand (N Y) 2013; 8 (03) 249-252 . Doi:10.1007/s11552-013-9526-5
• 12 Scott JW. Scott's parabola. BMJ 2001; 323 (7327): 1477 . DOI: 10.1136/bmj.323.7327.1477
• 13 Lipman MD, Carstensen SE, Deal DN. Trends in the Treatment of Dupuytren Disease in the United States Between 2007 and 2014. Hand (N Y) 2017; 12 (01) 13-20 . Doi:10.1177/1558944716647101
• 14 Thayer MK, Somerson JS, Huang JI. Changes in Provider Treatment Patterns for Dupuytren's Contracture: Analysis of Trends in Medicare Beneficiaries. Plast Reconstr Surg Glob Open 2018; 6 (10) e1932 . DOI: 10.1097/GOX.0000000000001932
• 15 Zhao JZ, Hadley S, Floyd E, Earp BE, Blazar PE. The Impact of Collagenase Clostridium histolyticum Introduction on Dupuytren Treatment Patterns in the United States. J Hand Surg Am 2016; 41 (10) 963-968 . Doi:10.1016/j.jhsa.2016.07.090
• 16 Crean SM, Gerber RA, Le Graverand MP, Boyd DM, Cappelleri JC. The efficacy and safety of fasciectomy and fasciotomy for Dupuytren's contracture in European patients: a structured review of published studies. J Hand Surg Eur Vol 2011; 36 (05) 396-407 . Doi:10.1177/1753193410397971
• 17 Sennwald GR. Fasciectomy for treatment of Dupuytren's disease and early complications. J Hand Surg Am 1990; 15 (05) 755-761
• 18 Lesiak AC, Jarrett NJ, Imbriglia JE. Modified McCash Technique for Management of Dupuytren Contracture. J Hand Surg Am 2017; 42 (05) 395.e1-395.e5 . Doi:10.1016/j.jhsa.2017.01.018
• 19 Arandes-Renú JM, Sanjuán-Cerveró R, Moya-Molinas I. Collagenase in Europe from the Experimental Phase to Practical Use. In: Pajardi G, Badalamente MA, Hurst LC. , eds. Collagenase in Dupuytren Disease. Cham: Springer International Publishing; 2018: 39-74 . doi:10.1007/978-3-319-65822-3_4
• 20 Eaton C. Dupuytren and Rare Disease Research. Dupuytren Research Group. https://dupuytrens.org/dupuytren-and-rare-disease-research/ . Published July 1, 2019. Accessed July 30, 2019.
• 21 Reichert B, Baringer M. [Preferred treatment options of German hand surgeons in Dupuytren disease]. Handchir Mikrochir Plast Chir 2018; 50 (03) 196-201 . Doi:10.1055/a-0645-7075
• 22 Marks M, Krefter C, Herren DB. [Treatment Methods for Patients with Dupuytren's Disease in Switzerland]. Handchir Mikrochir Plast Chir 2016; 48 (03) 155-160 . Doi:10.1055/s-0042-104056
• 23 Carr L, Michelotti B, Brgoch M, Hauck R, Ingraham J. Dupuytren Disease Management Trends: A Survey of Hand Surgeons. Hand (N Y) 2018; 1558944718787281 (July): 1558944718787281 . DOI: 10.1177/1558944718787281
• 24 McMillan C, Yeung C, Binhammer P. Variation in Treatment Recommendations for Dupuytren Disease. J Hand Surg Am 2017; 42 (12) 963-970.e6 . Doi:10.1016/j.jhsa.2017.08.023
• 25 Bainbridge C, Dahlin LB, Szczypa PP, Cappelleri JC, Guérin D, Gerber RA. Current trends in the surgical management of Dupuytren's disease in Europe: an analysis of patient charts. Eur Orthop Traumatol 2012; 3 (01) 31-41 . Doi:10.1007/s12570-012-0092-z
• 26 Dahlin LB, Bainbridge C, Leclercq C. , et al. Dupuytren's disease presentation, referral pathways and resource utilisation in Europe: regional analysis of a surgeon survey and patient chart review. Int J Clin Pract 2013; 67 (03) 261-270 . Doi:10.1111/ijcp.12099
• 27 Dias J, Bainbridge C, Leclercq C. , et al. Surgical management of Dupuytren's contracture in Europe: regional analysis of a surgeon survey and patient chart review. Int J Clin Pract 2013; 67 (03) 271-281 . Doi:10.1111/ijcp.12106
• 28 Moermans JP. Segmental aponeurectomy in Dupuytren's disease. J Hand Surg [Br] 1991; 16 (03) 243-254 . Doi:10.1016/0266-7681(91)90047-R
• 29 Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N. Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease. J Hand Surg Am 2010; 35 (12) 2027-38.e1 . Doi:10.1016/j.jhsa.2010.08.007